Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002040754 | SCV002299773 | likely pathogenic | Granulomatous disease, chronic, X-linked | 2020-12-06 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly20 amino acid residue in CYBB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9585602, 19410294, 20729109). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals with CYBB-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 2 of the CYBB gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. |